Peripheral blood regulatory T cell counts as a predictive biomarker for the outcome of kidney transplant: A systematic review

Herrera‐Gómez, Francisco; Vásquez-Seoane, Mónica; Aguila, Waldo del; Martín-García, Débora; Meiggs, Álvaro Maurtua-Briseño; González-López, Anunciación; Andrés-Martín, Beatriz; Nava-Rebollo, Álvaro; Casquero-Fernández, Fernando; Pascual-Núñez, Pilar; Grande-Villoria, Jesús; Bustamante-Bustamante, Jesús; Ochoa-Sangrador, Carlos; Lambert, Claude; Mendiluce-Herrero, Alicia

doi:10.1016/j.medcle.2017.11.019

Cited by 3 publications

(1 citation statement)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, compared to sirolimus, everolimus has a shorter half-life, a faster onset of steady state, and is suitable for combination therapy with CsA. Everolimus inhibits helper T cells and inhibits immune rejection (Herrera-Gómez et al., 2017 ) and tumor growth (Huijts et al., 2017 ), so it can be used for noninfectious uveitis (Li et al., 2018 ), autoimmune uveoretinitis, and corneal neoplasia immune-mediated rejection after corneal transplantation and angiogenesis (Blair et al., 2017 ).…”

Section: Everolimusmentioning

confidence: 99%

Research progress of ophthalmic preparations of immunosuppressants

Liu

Yan³

et al. 2023

Drug Delivery

View full text Add to dashboard Cite

Immune ophthalmopathy is a collection of autoimmune eye diseases. Immunosuppressants are drugs that can inhibit the body’s immune response. Considering drug side effects such as hepatorenal toxicity and the unique structure of the eye, incorporating immunosuppressants into ophthalmic nanodrug delivery systems, such as microparticles, nanoparticles, liposomes, micelles, implants, and in situ gels, has the advantages of improving solubility, increasing bioavailability, high eye-target specificity, and reducing side effects. This study reviews recent research and applications of this aspect to provide a reference for the development of an ophthalmic drug delivery system.

show abstract

Section: Everolimusmentioning

confidence: 99%

Research progress of ophthalmic preparations of immunosuppressants

Liu

Yan³

et al. 2023

Drug Delivery

View full text Add to dashboard Cite

show abstract

Preparation and study of two kinds of ophthalmic nano-preparations of everolimus

Yin

Zhang

et al. 2019

Drug Delivery

View full text Add to dashboard Cite

Objective: To prepare everolimus nanoformulations and increase their solubility to suit their application in the eye. Methods: The everolimus micelles was prepared by thin film dispersion method using Tween-80 (P80) and polyoxyethylene stearate (P40S) as carriers. In addition, the everolimus nanosuspension was prepared by injection method using poloxamer 407 (P407), hydroxypropyl methylcellulose (HPMC) and polyvinyl alcohol (PVA) as stabilizers. It was characterized in terms of particle size, PDI and encapsulation efficiency or drug loading. The in vitro release and in vitro rabbit scleral permeability characteristics were investigated, and the pharmacokinetics of anterior chamber drug in rabbit eyes were studied. Results: The average particle size of the micelles was (8.74 ± 0.21) nm, the encapsulation efficiency and drug loading were (90.12 ± 1.18)% and (2.14 ± 0.028)%, while the average particle size of the nanosuspension was (156.47 ± 1.10) nm, and the drug loading was (16.51 ± 0.21)%, respectively. Both in vitro release and rabbit scleral permeation models were consistent with the Higuchi equation. The pharmacokinetic experiments of aqueous humor showed that area under the curve of everolimus nanosuspension was about 3 times higher than that of micelles. Micelles could be achieved in the eye and maintained for a long time. Conclusion: The preparation of everolimus micelles or nanosuspension for eye are suitable for ocular administration and expected to be new dosage form for corneal transplantation immunological rejection or other ocular disease. ARTICLE HISTORY

show abstract

Effect of Calcineurin Inhibitors and Mammalian Target of Rapamycin Inhibitors on the Course of COVID-19 in Kidney Transplant Recipients

et al. 2021

View full text Add to dashboard Cite

Coronavirus disease 19 (COVID-19) has been an ongoing pandemic since December 2019. Unfortunately, kidney transplant recipients are a high-risk group during the disease course, and scientific data are still limited in this patient group. Beyond the dosage of immunosuppressive drugs, pharmacological immunosuppression may also alter the infection response in the COVID-19 course. The effects of immunosuppressive agents on the development and process of infection should not be decided only by determining how potent they are and how much they suppress the immune system; it is also thought that the direct effect of the virus, increased oxidative stress, and cytokine storm play a role in the pathogenesis of COVID-19 disease. There are data about immunosuppressive drugs like calcineurin inhibitors (CNI) or mammalian target of rapamycin inhibitors (mTORi) therapy related to their beneficial effects during any infection course. Limited data suggest that the use of CNI or mTORi may have beneficial effects on the process. In this hypothetical review, the probable impacts of CNI and mTORi on the pathogenesis of the COVID-19 were investigated.

show abstract

Peripheral blood regulatory T cell counts as a predictive biomarker for the outcome of kidney transplant: A systematic review

Cited by 3 publications

References 50 publications

Research progress of ophthalmic preparations of immunosuppressants

Research progress of ophthalmic preparations of immunosuppressants

Preparation and study of two kinds of ophthalmic nano-preparations of everolimus

Effect of Calcineurin Inhibitors and Mammalian Target of Rapamycin Inhibitors on the Course of COVID-19 in Kidney Transplant Recipients

Contact Info

Product

Resources

About